Buchumschlag

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

Weitere Versionen anzeigen (1)

Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimuma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Meindl-Beinker, Nadja M. (VerfasserIn) , Betge, Johannes (VerfasserIn) , Gutting, Tobias (VerfasserIn) , Burgermeister, Elke (VerfasserIn) , Belle, Sebastian (VerfasserIn) , Zhan, Tianzuo (VerfasserIn) , Schulte, Nadine (VerfasserIn) , Ebert, Matthias (VerfasserIn) , Härtel, Nicolai (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 14 March 2019
In: BMC cancer
Year: 2019, Jahrgang: 19
ISSN:1471-2407
DOI:10.1186/s12885-019-5446-2
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-019-5446-2
Volltext
Verfasserangaben:Nadja M. Meindl-Beinker, Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, Martin Maenz, Matthias P. Ebert and Nicolai Haertel
Beschreibung
Zusammenfassung:Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimumab as 2nd line therapy in elderly ESCC patients.
Beschreibung:Gesehen am 10.04.2019
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-019-5446-2

Ähnliche Einträge